That helped investors who began 2019 with shares of Crispr Therapeutics (NASDAQ: CRSP) and Editas Medicine (NASDAQ: EDIT), two gene-editing ...
Source link
That helped investors who began 2019 with shares of Crispr Therapeutics (NASDAQ: CRSP) and Editas Medicine (NASDAQ: EDIT), two gene-editing ...
Source link